Business

Piramal Pharma completes acquisition of Hemmo Pharmaceuticals

Piramal Pharma has completed the acquisition of Hemmo Pharmaceuticals Private Ltd for cash consideration of Rs 775 crore and earn-outs linked to achievement of milestones.

migrator

Updated:23rd Jun, 2021 at 4:16 PM

Mumbai

In March, Piramal Enterprises, the parent company of Piramal Pharma, had announced the proposed acquisition.

"We wish to inform you that PPL has completed the acquisition of Hemmo on 22nd June, 2021 and the transaction is now closed," Piramal Enterprises said in a regulatory filing on Wednesday.

The development marks Piramal Pharma's foray into manufacturing of peptide APIs (active pharmaceutical ingredients), complementing its existing offerings.

Hemmo is one of the few pure-play synthetic peptide API manufacturers in the global marketplace. With the addition of Hemmo's capabilities, PPS would gain access to the growing peptide API market and enhance its ability to offer integrated services to its customers globally.

Around 10.40 a.m., shares of Piramal Enterprises on the BSE were trading at Rs 2,454.90, higher by Rs 8.70 or 0.36 per cent from its previous close.

Piramal Pharma completes acquisition of Hemmo Pharmaceuticals

Piramal Pharma has completed the acquisition of Hemmo Pharmaceuticals Private Ltd for cash consideration of Rs 775 crore and earn-outs linked to achievement of milestones.

Also Read

Cyclone Murasu: TN rushes 500 electricity dept personnel, equipment to AP to restore power

SC dismisses petition filed by former DMK minister Nehru in cash-for-job scam

DMK chief Stalin slams TVK govt over GST slump, loss of Rs 1,614 crore Korean investment to AP

CM Vijay inaugurates Rs 23 crore bus stand in Pudukottai

TASMAC retail outlets remain State-run as govt revises rules for private bars